Latest International Expansion News

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Advanced Braking Technology (ASX: ABV) posted a record $6.2 million in product sales for Q4 FY26, lifting full-year revenue 22.7% to $23.5 million. The company’s autonomous BRAKEiQ system advanced key milestones as international engagement expanded.

Sprintex boosted its commercial footprint in the June quarter with a 65% order book increase from Mest Water, a paid trial at Taiwan's TSMC, and Dutch regulatory clearance lifting key uncertainties.

xReality Group delivered a robust Q4 FY26, with cash receipts up 46% to $6.9 million and net operating cash flow rising 64% to $2.2 million. The company completed a $5.6 million US Department of Defense project on time and secured its first European contract with the Swedish Armed Forces.

Saluda Medical capped FY26 with a 28% revenue surge, beating guidance at US$90.2 million, while FDA approval for its CAP24 paddle lead opens a new US surgical market segment.

The Calmer Co International Ltd is raising up to $3.5 million through a 1-for-1 renounceable entitlement offer priced at $0.001 per share, including free attaching options exercisable at $0.002. The capital will fund debt repayment, inventory expansion, marketing, and product launches.

Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.

Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

I Synergy Group has appointed Anson Heng as Executive Chairman and Managing Director to spearhead its strategic cooperation with Macau Direch, formalised through a non-binding MoU targeting blockchain, AI, and digital asset initiatives.

Global Health Limited boosted customer receipts by 12.6% to A$9.53 million for FY26, completing its SaaS platform upgrade and cutting cash burn by 30%. The company targets sustained EBITDA profitability and international expansion in FY27.